FDA “PreCheck” for drug plants
The FDA is launching a fast-lane to help companies build U.S. medicine factories quicker. Goal: fewer shortages and more drugs made at home.

First-ever drug for a deadly brain tumor
Jazz won approval for the first treatment aimed at a tough brain cancer seen in kids and adults. It’s not a cure, but it finally gives doctors something to use.

Chikungunya vaccine back for seniors (with warnings)
U.S. officials lifted a pause on Valneva’s shot for older adults after review. It’s now meant for people at high risk (think travelers to outbreak areas), with added safety guidance.

Twice-a-year HIV prevention shot is taking off
Gilead’s new PrEP injection, given every 6 months, is beating early sales expectations. Convenience looks like a big driver.

Medicare drug price talks keep winning in court
More legal challenges against the price-negotiation law just failed. Bottom line: the government’s bargaining power is holding.

Doximity buys an AI medical “answer engine”
The doctors’ app snapped up Pathway Medical to give clinicians quicker, evidence-based answers inside their workflow. Expect faster, clearer point-of-care lookups.

FTC tries to block a heart-valve merger
Regulators moved to stop Edwards from buying JenaValve to keep competition (and innovation) alive in heart devices. The companies plan to fight it.

UnitedHealth can buy Amedisys—if it sells sites
DOJ would allow the $3.3B deal as long as UnitedHealth divests a bunch of home-health and hospice locations. A carve-out to prevent local monopolies.

Flesh-eating bacteria cases rising on Gulf Coast
Infections tied to warm, brackish water are up. If you have an open cut, skip wading; if you get red, painful swelling after exposure, seek care fast.

Lower-cost Actemra “look-alike” gets a bigger label
A tocilizumab copycat now covers treatment of cytokine release syndrome (the dangerous “immune storm”). That could broaden access and save hospitals money.